Cargando…

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

The association of microRNA alterations with progression and treatment outcome has been revealed in different types of cancers. To find miRNAs involved in imatinib response we performed miRNA microarray followed by RT-qPCR verification of 9 available diagnostic bone marrow core biopsies from 9 CML p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mosakhani, Neda, Mustjoki, Satu, Knuutila, Sakari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751646/ https://www.ncbi.nlm.nih.gov/pubmed/23866735 http://dx.doi.org/10.1186/1755-8166-6-27

Ejemplares similares

Downregulation of Plasma MiR-142-3p and MiR-26a-5p in Patients With Colorectal Carcinoma
por: Ghanbari, Reza, et al.
Publicado: (2015)

Immune control in chronic myeloid leukemia
por: Ilander, Mette, et al.
Publicado: (2017)

MicroRNA-181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib
por: WANG, GUANGYU, et al.
Publicado: (2015)

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
por: Ohyashiki, Kazuma, et al.
Publicado: (2016)

Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia
por: Huang, Xiaomeng, et al.
Publicado: (2016)

PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration
por: Su, Rui, et al.
Publicado: (2023)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Overexpression of miR-202 resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2
por: Deng, Yingjun, et al.
Publicado: (2018)

Gynecomastia in a Boy with Chronic Myeloid Leukemia during Imatinib Therapy
por: Tavil, Betül, et al.
Publicado: (2013)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Acquisition of mixed lineage leukemia rearrangement in a chronic myeloid leukemia patient while on imatinib
por: Zámečníkova, Adriana
Publicado: (2011)

CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
por: Landberg, Niklas, et al.
Publicado: (2018)

MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia
por: Visone, Rosa, et al.
Publicado: (2012)

IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia
por: Ilander, Mette, et al.
Publicado: (2014)

The Inhibitory Effect of Sulforaphane on The Proliferation of Acute Myeloid Leukemia Cell Lines through Controlling miR-181a
por: Koolivand, Mohsen, et al.
Publicado: (2022)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate
por: Martins, Juliana R. B., et al.
Publicado: (2021)

Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance
por: Wu, Yi-Ying, et al.
Publicado: (2021)

miR-181d/RBP2/NF-κB p65 Feedback Regulation Promotes Chronic Myeloid Leukemia Blast Crisis
por: Zhou, Minran, et al.
Publicado: (2021)

PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b
por: Baghbani, Elham, et al.
Publicado: (2018)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia
por: Vargova, K, et al.
Publicado: (2017)

SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia
por: Albano, Francesco, et al.
Publicado: (2012)

Roles of hsa-miR-12462 and SLC9A1 in acute myeloid leukemia
por: Jia, Yan, et al.
Publicado: (2020)

Concomitant ATM Mutations Identified by Next Generation Sequencing in a Patient With New-Onset Acute Myeloid Leukemia Following Imatinib Treatment for Chronic Myeloid Leukemia
por: Stein, Matthew K., et al.
Publicado: (2018)

Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia
por: Durmaz, Burak, et al.
Publicado: (2021)

Induction of K562 Cell Apoptosis by As(4)S(4) via Down-Regulating miR181
por: Gong, Jiangjiang, et al.
Publicado: (2017)

Clinical significance of miR-372 and miR-495 in acute myeloid leukemia
por: Zhang, Wei, et al.
Publicado: (2020)

Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia
por: Zhao, Lifen, et al.
Publicado: (2016)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
por: Ilander, M, et al.
Publicado: (2017)

Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation
por: Shen, Qi, et al.
Publicado: (2013)

MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia
por: Krowiorz, K, et al.
Publicado: (2016)

Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia
por: Moshfeghi, Kamran, et al.
Publicado: (2013)

An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma
por: Mosakhani, Neda, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p04ohkphojlpv13eorq923p8vu